175results about How to "Has clinical application value" patented technology

The invention is applicable to the field of medical image processing, and provides a processing method and a processing system for dividing liver graphs of a CT (computed tomography) image. The processing method includes steps of acquiring the to-be-divided image; automatically positioning a liver position in the to-be-divided image by preliminarily testing a liver grayscale volume and liver grayscale; registering and extracting initial liver tissue graphs by rotary registering and sampling bands B with low degrees of freedom; combining distance graphs with the initial extracted liver tissue graphs to detect whether the graphs contain liver tumor tissue graphs or not; and precisely dividing the liver graphs in a registering manner by the aid of a liver distribution probability map and the sampling bands B based on mutual information. The processing method and the processing system have the advantages that manual intervention is omitted in an integral dividing procedure, the average volumetric error of the divided liver graphs is about 7.0%, accurate data can be provided for three-dimensional reconstruction and final simulation surgery for livers of patients, and the processing method and the processing system have certain clinical application value.

The invention discloses a preparation method of a medical hemostatic occlusion dressing. The preparation method comprises the following steps: (1), taking and pouring deionized water into a reactor, heating the reactor, slowly adding lemon peel pectin and gelatin, and mechanically stirring at the same time; (2), after the addition of the lemon peel pectin and gelatin, stirring continuously, then adding other components into the reactor, and carrying out mechanical stirring uniformly at the same time; (3), after the mixing of the materials, cooling hydrogel to be at a room temperature, so as to obtain the medical hemostatic occlusion dressing. The medical hemostatic occlusion dressing prepared through the method provided by the invention is high in bleeding stopping speed, has auxiliary functions of promoting wound surface healing, preventing adhesion and the like, is also better in biomechanics and air permeability, and has an important clinical application value; the preparation method provided by the invention has the advantages that the process is simple, requirements for equipment are relaxed, raw materials are low in cost and readily available, the cost is low, and industrialization is easy to realize.

The invention relates to a novel cationic graft copolymer, and a preparation method and an application of a multiple composite non-viral gene vector. The novel cationic graft copolymer PCL-g-LPEI (polycaprolactone-g-linear polyethylenimine) is synthesized by ring-opening copolymerization and amidation reaction. The multiple composite non-viral gene vector comprises: (A) a plasmid DNA (deoxyribonucleic acid)-supported PCL-g-LPEI cationic compound serving as a kernel of a multiple gene compound; (B) a tumor-targeting ligand HA (hyaluronic acid) wrapping the cationic compound under the interaction of positive and negative charges to form a shell of the multiple gene compound. A multiple composite gene constructed by the non-viral gene vector has the advantages of low cytotoxicity, high blood compatibility, high transfection efficiency, tumor targeting effects and the like, and is expected to be applied to clinical gene therapy.

The invention discloses an application of a guanidino compound represented by formula I or a pharmaceutically acceptable salt of the guanidino compound in the preparation of medicines for treating nervous system degenerative diseases. R in the formula I is hydrogen, a carboxyl group or a -C1~C5 alkyl-carboxyl group. The guanidino compound has a substantial protection effect on hydrogen peroxide induced neonatal rat hippocampal nerve cell injures, has a substantial inhibition effect on in vitro beta-amyloid protein aggregation, and has potential clinic application values.

The invention relates to a prognosis prediction model for patients with hilar cholangiocarcinoma. Specifically, the present invention provides a carrier for postoperative prognosis of patients with hilar cholangiocarcinoma, which is used to calculate risk factor scores and patient 3-year survival rate Y3 and/or 5-year survival rate Y5; Wherein, the risk factors include at least the patient's age X, and the fraction of the patient's age, the 3-year survival rate and the 5-year survival rate satisfy the relationship described in the article. The present invention systematically investigates the clinical and pathological characteristics that affect the prognosis of patients with hilar cholangiocarcinoma, and the effect of patients after surgical treatment, evaluates the key factors that affect the survival and prognosis of patients with hilar cholangiocarcinoma, and establishes a method for patients with hilar cholangiocarcinoma. The list of survival prognosis is used to evaluate the 3-year and 5-year survival rate of patients after surgery, and to screen out high-risk groups for intervention to improve the survival prognosis of patients.

The invention discloses a method for regenerating a dental prosthetic material and an acidic amino acid-induced demineralized dental enamel outer enamel prism thereof in situ, and belongs to the technical field of in-situ regeneration of dental enamel outer enamel prisms. The preparation method is as follows: firstly, carrying out surface calcium activation onto a dental enamel surface, i.e., grafting calcium ions; then, forming calcium carbonate stable calcium ions step by step; finally, taking calcium carbonate stable calcium ions as foundation forms to synthesize hydroxyapatite crystals. Amino acid participates in the whole process, concentration of the amino acid added in a two-step process is consistent. The hydroxyapatite crystals deposited on the surface of the demineralized dental enamel are orderly and compact in sequence, and uniform in crystal morphology, so that obvious continued growth tendency of an artificial layer can be seen. The preparation method disclosed by the invention lowers protein extracting cost and harsh restrictions on an application environment, and is wide in prospect. The material prepared by the method disclosed by the invention can be applied to cosmetic dental for filling demineralization gaps, also can be used for repairing early-stage enamel demineralization, and can be used as a combined material for bottom pulp capping pit and fissure sealing, and the like.

The invention discloses a feature data mining and neural network-based tumor classification method. The method includes the following steps that: the man-made scoring data of the effective lesion features of a tumor ultrasonic image are selected as an original feature data set; a bi-clustering algorithm is adopted to acquire effective local diagnosis modes from the original training data set; features of higher levels are extracted according to the effective local diagnosis modes, so that new feature vectors are formed; with the new feature vectors adopted as the input of a neural network, training is carried out, so that an effective multi-class classifier can be obtained; and feature vectors are extracted from a test sample by using the same manner mentioned above, and the multi-class classifier which is obtained through training is utilized to classify the feature vectors, and the specific classification result of a tumor can be obtained. With the feature data mining and neural network-based tumor classification method adopted, the defect that a traditional computer-assisted method is limited to low-level image features can be eliminated; and higher-level effective features are mined from a large number of man-made scoring feature data sets, and the classifier which can identify many types of tumors can be obtained through training by using a popular neural network classification method.

The invention belongs to the field of gene detection, and in particular relates to a multiplex PCR (polymerase chain reaction) kit for detecting leukemia fusion genes. The kit comprises a conventional multiplex PCR component, and chimeric primer and common primer pairs aiming at the common leukemia fusion genes. Chimeric primers are sequences of adding common primers to the 5' ends of specific primers of seven shear isomers of the common leukemia fusion genes BCR/ABL, PML/RARalpha, AML1/ETO and E2A/PBX1. By using the multiplex PCR kit for detecting the leukemia fusion genes, seven leukemia fusion genes including AML1/ETO, BCR/ABLe1a2, BCR/ABLe13a2, BCR/ABLe14a2, PML/RARalphaL, PML/RARalphaS and E2A/PBX11 with high incidence can be simultaneously detected, so that the consumption of reagents can be saved, the detection cost can be reduced, and meanwhile, the detection efficiency is improved. Moreover, the highest detection sensitivity of the kit can reach 10 copies per 25mu L, and the kit is simple in operation and high in clinical detection rate, so that the kit has clinical popularization and application values.

The invention discloses medicine-carried mesoporous silica coated polypyrrole nanoparticles and a preparation method thereof. The preparation method comprises preparation of polypyrrole nanoparticlesand preparation of the medicine-carried mesoporous silica coated polypyrrole nanoparticles. The medicine-carried mesoporous silica coated polypyrrole nanoparticles prepared by the preparation method disclosed by the invention are simple in preparation process, low in production cost and easy in industrial production. On the one hand, the novel nano preparation enters the tumor stroma through an EPR (Enhanced Permeability and Retention) effect of a tumor site to realize passive targeted drug delivery of the tumor, thereby improving the bioavailability of the drug, reducing the toxic and side effects of the drug and enhancing the therapeutic action of the drug; and on the other hand, polypyrrole coated in the novel nano preparation has very high photothermal conversion efficiency, so that the novel nano preparation can simultaneously perform photothermal therapy and realize photoacoustic imaging and has potential clinical application values.

The invention relates to a cancer diagnosis technology, in particular to application of serum IL-6 in the preparation of a primary hepatocellular carcinoma diagnostic reagent kit. The reagent kit can quickly and accurately detect the IL-6, thereby performing quick assistant diagnosis to primary hepatocellular carcinoma at each stage (particularly at early stage) and having important clinical application value. The invention comprises the establishment of an enzyme-linked immune diagnosis system based on a double antibody sandwich principle. The serum does not need to be diluted, so the sensitivity is greatly improved. The application has the advantages that the detection reagent kit has simple operation, steady reagent, good repetitiveness, strong specificity, and high sensitivity, is easy to promote and apply within large range, and has broad market prospect.

The invention discloses a kit for chemiluminescent quantitative immunoassay of a free beta-human chorionic gonadotrophin (hCG). The kit comprises a free beta-hCG antibody-coated plate, a free beta-hCG antibody enzyme conjugate, a free beta-hCG calibrator, a free beta-hCG quality control material, a washing liquid concentrated by 20 times, a light-emitting solution A and a light-emitting solution B. The kit has the advantages of high detection sensitivity, low cost and simple and fast operation, and has a high clinical application value. The invention also discloses a preparation method of the kit.

The invention relates to a cell membrane coated ultra-small ferroferric oxide nanocluster, and a preparation method and an application thereof. The method comprises the following steps: preparation ofultra-small ferroferric oxide nanoparticles, preparation of surface aminated ultra-small ferroferric oxide nanoparticles, preparation of ferroferric oxide nanoclusters, preparation of adriamycin-loaded ferroferric oxide nanoclusters, preparation of a cell suspension, and preparation of cell membrane coated ultra-small ferroferric oxide nanoclusters. After the nanocluster provided by the inventionis injected into a mouse body through a tail vein, T1/T2 bimodal MR imaging conversion can be achieved; meanwhile, the anti-tumor effect can be exerted; the chemotherapy effect of the nanocluster canbe further enhanced through a UTMD auxiliary means; and the nanocluster has potential clinical application value.

The embodiment of the invention discloses a method for purifying cord blood mononuclear cells. The method comprises: step 1, centrifuging human umbilical cord blood to obtain blood cells and plasma; step 2, subjecting the blood cells to erythrocyte sedimentation with hydroxyethyl starch to obtain a lymphocyte suspension; and step 3, performing gradient centrifugal separation on the lymphocyte suspension by using a Ficoll reagent so as to obtain the cord blood mononuclear cells. The method can effectively reduce the number of erythrocyte and thrombocyte in the final product, and the number of the purified cord blood mononuclear cells is large, and the purity and the motility rate are high.

The invention discloses a multiplex-PCR kit for rapid diagnosis of viral encephalitis. With the application of the multiplex-PCR kit, six viral encephalitis, namely herpes simplex virus type 1 (HSVI), herpes simplex virus type 2 (HSVII), varicella-zoster virus (VZV), EB virus (EBV), enterovirus type 71 (EV71) and cytomegalovirus (CMV), can be rapidly detected; the HSVI, the HSVII, the EBV, the CMV, the EV71 and the VZV are specifically amplified by virtue of six pairs of primers provided by the invention, the primers are free from mutual interference, and the sensitivity of a constructed mPCR system reaches 102-103 copies; for 15 cases of cerebrospinal fluid specimens from patients with suspected clinical viral encephalitis, 6 parts of positive specimens, including 5 cases of HSVI and 1 case of CMV, are detected by virtue of the mPCR system; the mPCR system designed by the invention has the advantages of being high in sensitivity, specificity and stability and being simple to operate; and the six common viruses can be simultaneously detected rapidly; therefore, the multiplex-PCR kit is conducive to rapid diagnosis of the viral encephalitis.

VB12 The invention discloses a quantitative determination kit of chemiluminescence immunoassay for Vitamin B12 (VB 12), comprising a VB 12 antibody coated plate, an enzyme conjugated VB 12, a VB 12 calibration material, a quality control material, 20 times concentrated washing liquor, luminescent liquors A and B, and sample treatment fluids A and B. additionally, the invention also discloses a method for preparing the VB 12 chemiluminescence immune quantitative determination kit. The advantages of the kit over the prior art are simple operation, and safety and no environmental pollution. Moreover, the kit has the advantages of ability for samples of broad concentration range detection, long effective period, good stability, low cost and the like.

The invention relates to a cell factor FAM19A4 with anti-infection and antineoplastic activity and application thereof. Specifically speaking, the invention provides a gene or protein of FAM19A4 or immunological fragments thereof, genetic engineering vectors and host cells including the gene or protein of FAM19A4 or the immunological fragments thereof and antibodies to the protein of FAM19A4 or the immunological fragment thereof. The invention further provides application of the gene or protein of FAM19A4 or the immunological fragments thereof in preparation of medicinal preparations having antiviral, anti-endocellular bacterial, antimycotic, anti-extracellular bacterial and antineoplastic effects. Furthermore, the invention also provides application of a detection reagent in preparation of compositions used for auxiliary diagnosis and prognosis of diseases related to immunization.

The invention discloses application of lncRNA SGOL1-AS1 serving as a marker for diagnosing stomach cancer. The cDNA sequence of the lncRNA SGOL1-AS1 is as shown in SEQ ID NO:1. The invention discoversapplication of the lncRNA SGOL1-AS1 or a fragment thereof serving as a marker for diagnosing stomach cancer. A stomach cancer diagnosing kit constructed by the invention comprises a pair of specificdetection primers which can be used for detecting tissue specimens as well as blood specimens such as plasma, serum and platelet. A non-invasive diagnostic mode aiming at blood specimens has better clinical application value, can achieve a good detection effect at the early stage of stomach cancer, and has very high popularization value.

The invention belongs to the field of pharmaceutical chemistry, particularly relates to compounds with TLR (Toll-like receptor) modulation effect as well as a preparation method and an application ofthe compounds, and provides compounds represented by the following formula X in the description. The compounds of formula X can be used as the TLR modulators and have higher activity. Besides, the compounds have the characteristics of high efficiency, low toxicity, resistance to drug resistance and the like, and have clinical application value. Moreover, synthesis steps of the compounds are simple, so that the compounds have higher economic utilization value.

The invention belongs to the biomedical field and provides a subunit mixed vaccine of the human enterovirus 71. The subunit mixed vaccine contains one or more of the polypeptides of the human enterovirus 71 polypeptide chain and necessary adjuvants, wherein the polypeptides are P1-69, P70-159, P140-249, P324-433, P444-565, P566-665, P746-876, P1197-1338, P1441-1526, P1549-1668, P1649-1731, P1732-1851, P1952-2071, P2072-2193 and P1843-1951. The vaccine has no potential toxic or side effect, has the protective function of anti-virus infection in vitro and in vivo and is a vaccine candidate with the potential clinical application value.

The invention relates to a purpose of CYR61 protein, in particular to an application of CYR61 protein in the pharmaceutical field. The adopted technical proposal is an application of the CYR61 protein in the preparation of medicaments for rheumatic diseases, and the rheumatic diseases refer to chronic infectious arthritis. The invention has the advantages of developing the medical purpose of the CYR61 and opening a new application field. Results of the invention indicate that the CYR61 has the functions of promoting the proliferation of fibroblast-like synoviocytes (FLS) and participating in the damages to articular cartilages and bone tissues. One method for realizing the functions is to promote the fibroblast-like synoviocytes to proliferate by inhibiting the apoptosis of synoviocytes, and the other method is to participate in the damages to articular cartilages and bone tissues by up-regulating metalloproteinase. The result provides test basis for finding biological therapeutic targets and therapeutic targets of other small-molecule medicaments, thereby having the clinical application values.

The invention discloses a three-dimensional connective porous artificial bone scaffold as well as a preparation method and application thereof and belongs to the technical field of biological materials. The magnesium-containing beta-TCP (beta-tertiary calcium phosphate) artificial bone scaffold is prepared by utilizing the unique microscopic structure of natural sea urchin and the hydro-thermal synthesis, and is of a three-dimensional connective porous structure, wherein the porosity is 50-70 percent, and the structure is beneficial to new bone regeneration in bone defect repairing. The three-dimensional connective porous artificial bone scaffold comprises granular and cylindrical artificial bone materials, a porous artificial bone scaffold for filling an interbody fusion cage and the like, and is applicable to bone defect filling, small-cake bone replacing and spinal fusing. Compared with an existing pottery firing method, the preparation method has the advantages that the experimental process is remarkably simplified, and artificial bone materials with different shapes and sizes for meeting requirements of bone injured patients can be produced by means of mechanical processing, and has important clinical application value.

The invention discloses porrigo-diminishing soup for treating psoriasis, which is prepared from the following raw materials in portion by weight: 8 to 12 portions of Schizonepeta tenuifolia, 8 to 12 portions of saposhnikovia root, 4 to 8 portions of radix paeoniae rubra, 13 to 17 portions of red sage root, 8 to 12 portions of Chinese angelica, 3 to 8 portions of liquorice, 10 to 14 portions of glabrous greenbrier rhizome, 10 to 14 portions of cortex dictamni, 10 to 14 portions of dried rehmannia rhizome and 3 to 7 portions of muscardine silkworm. A preparation method comprises the following steps: using water to decoct the raw materials twice, wherein the raw materials are decocted for 25 to 30 minutes for the first time, and for 10 to 15 minutes for the second time; and merging and uniformly mixing decoction solution of the two times. When the porrigo-diminishing soup for treating the psoriasis is used, one dosage is taken per day, is approximately 300 milliliters, and is taken for two times, namely in the morning and at the night. The porrigo-diminishing soup is safe and effective to treat the psoriasis, has no toxic and side effect, and has low price and promotion value and clinical application value.

The invention discloses an improved method for cultivating NK (natural killer) cells. The improved method has the advantages that sufficient quantities of the NK cells can be cultivated by the aid of the improved method in a separation manner, the improved method is high in amplification speed, and 70 billion cells can be generally cultivated in peripheral blood in 15 days; acetylated alpha glucan which is used as an activating mobilizing agent is added into media, accordingly, the NK cells can be successfully activated and can be promoted to secrete IL2, IL12 and IFN-gamma, critical effects for maintaining the activity of the NK cells and the amplification rates after the NK cells are activated can be realized by the IL2, the IL12 and the IFN-gamma, and the improved method has clinical application value; the NK cells obtained by the aid of the improved method are high in purity, as discovered via analysis on detection results of flow cell meters, the CD3<->CD56<+> NK cell population can reach 80% at least, and accordingly clinical application requirements can be met.